There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 2 | 588 | 86.66 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| Ask | Qty | Orders |
|---|---|---|
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
Annual Revenue,rose 5.45%, in the last year to ₹312.96 Cr. Its sector's average revenue growth for the last fiscal year was 12.13%.Annual Net Profit,rose 2.16% in the last year to ₹317.38 Cr. Its sector's average net profit growth for the last fiscal year was 1.9%.Price to Earning Ratio,is 7.05, lower than its sector PE ratio of 44.99.Alembic Pharmaceuticals Limited, established in 1907 and headquartered in Vadodara, Gujarat, is a research-driven integrated pharmaceutical company. It operates FDA-approved manufacturing facilities and R&D centers in Vadodara and Hyderabad, focusing on generic formulations and Active Pharmaceutical Ingredients (APIs). Its operations are structured into three verticals: Domestic Branded Business, International Generics, and APIs.
The portfolio spans therapy areas including Cardiology, Orthopaedics, Anti-Diabetic, Ophthalmology, Gynaecology, Nephrology, Gastrology, Urology, Dermatology, Anti-Infective, Cold & Cough, and Animal Health. Alembic serves 76 international markets, with exports contributing 57% of FY25 turnover. Four flagship brands crossed ₹1 billion in sales (per IPM). The company manages 204 brands, including 28 leaders, 24 ranked among the top three in their molecule group, and 73 generating over ₹10 crore revenue.
As of March 31, 2025, Alembic reports nine manufacturing facilities, 16,500+ employees, 915+ R&D personnel, and 756 cumulative filings (US 266; RoW 490).
For Q4 FY26, Alembic Ltd reported: Revenue (Net Sales): ₹577.30 Cr - Down -20.13% year-on-year from ₹722.80 Cr in Q3 FY26. Net Income (PAT): ₹95.30 Cr - Down -57.19% year-on-year from ₹222.60 Cr in Q3 FY26.
Yes,Alembic Ltd has declared a consistent dividend every year over the past 5 years. The company paid a total dividend of 11.20 per share between FY2022 and FY2026, with the most recent dividend of ₹2.40 per share for May 26, with an ex-dividend date of 04 Aug 2026. At the current market price of ₹86.70, the trailing dividend yield of Alembic Ltd stands at 4.80%.
Alembic Ltd has delivered a -26.40% absolute return over the past 5 years, equivalent to a CAGR of -5.95% per annum. The stock was priced at ₹117.80 in Aug 2021 and has fallen to ₹86.70 as of 06 Aug 2026. An investment of ₹1,00,000 in Alembic Ltd five years ago would be worth ₹73,600.00 today.
The all-time high (ATH) for Alembic Ltd was ₹164.17, recorded on 23 Aug 2024. At the current price of ₹86.70, the stock is trading 47.19% below its all-time high. The all-time low recorded was ₹7.03 on 06 Jan 2012.
Alembic Ltd has delivered -20.06% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹110.56 on 12 Aug 2025 and a 52-week low of ₹70.46 on 30 Mar 2026. It is currently trading at ₹86.70 as of 06 Aug 2026.
The intraday low for Alembic Ltd on the NSE today was ₹86.50. The stock's 52-week low stands at ₹70.46, recorded on 30 Mar 2026. Today's low is 22.76% above the 52-week low, indicating the stock is trading well above its yearly lows.
Alembic Ltd has delivered a return of -6.38% over the last 3 months. The stock was trading at ₹93.08 on 06 May 2026 and is currently at ₹86.70 as of 06 Aug 2026, reflecting a Loss of ₹6.38 per share over this period.
Over the last 6 months, Alembic Ltd has given a return of -10.28%. The stock was priced at ₹97.12 on 06 Feb 2026 and has Fallen to ₹86.70 as of 06 Aug 2026, a change of ₹10.42 per share.
The intraday high for Alembic Ltd on the NSE today (06 Aug 2026) was ₹89.10. This compares to the 52-week high of ₹110.56 recorded on 12 Aug 2025. Today's high was -19.41% below the 52-week high.
As of 06 Aug 2026, the share price of Alembic Ltd is ₹86.70 on the NSE and ₹86.50 on the BSE. The stock opened at ₹87.50, touched a high of ₹89.10 and a low of ₹86.50 during today's session.
